Post-earnings recap
Reported
Wed, Aug 3, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share that was slightly better than expected, but the lack of revenue data and guidance contributed to a negative stock reaction. The stock fell by 3.76%, reflecting investor concerns about the company's future performance and clarity on its financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | +4.93% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without providing specific guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs.